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Abstract
Background: Little is know about the outcomes of acute heart failure (AHF) with acute coronary syndrome
(ACS-AHF), compared to those without ACS (NACS-AHF).
Methods: We conducted a prospective registry of AHF patients involving 18 hospitals in Saudi Arabia between
October 2009 and December 2010. In this sub-study, we compared the clinical correlates, management and
hospital course, as well as short, and long-term outcomes between AHF patients with and without ACS.
Results: Of the 2609 AHF patients enrolled, 27.8 % presented with ACS. Compared to NACS-AHF patients, ACS-AHF
patients were more likely to be old males (Mean age = 62.7 vs. 60.8 years, p = 0.003, and 73.8 % vs. 62.7 %, p < 0.001,
respectively), and to present with De-novo heart failure (56.6 % vs. 28.1 %, p < 0.001). Additionally they were more
likely to have history of ischemic heart disease, diabetes, dyslipidemia, and less likely to have chronic kidney disease
(p < 0.001 for all comparisons). The prevalence of severe LV systolic dysfunction (EF < 30 %) was higher in ACS-AHF
patients. During hospital stay, ACS-AHF patients were more likely to develop shock (p < 0.001), recurrent heart failure
(p = 0.02) and needed more mechanical ventilation (p < 0.001). β blockers and Angiotensin Converting Enzyme
inhibitors were used more often in ACS-AHF patients (p = 0.001 and, p = 0.004 respectively). ACS- AHF patients
underwent more coronary angiography and had higher prevalence of multi-vessel coronary artery disease (p < 0.001
for all comparisons). The unadjusted hospital and one-month mortality were higher in ACS-AHF patients (OR = 1.6
(1.2–2.2), p = 0.003 and 1.4 (1.0–1.9), p = 0.026 respectively). A significant interaction existed between the level of left
ventricular ejection fraction and ACS-AHF status. After adjustment, ACS-AHF status was only significantly associated
with hospital mortality (OR = 1.6 (1.1–2.4), p = 0.019). The three-years survival following hospital discharge was not
different between the two groups.
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Conclusion: AHF patients presenting with ACS had worse hospital prognosis, and an equivalent long-term survival
compared to AHF patients without ACS. These findings underscore the importance of timely recognition and
management of AHF patients with concomitant ACS given their distinct presentation and underlying pathophysiology
compared to other AHF patients.
Keywords: Heart failure complications/mortality/physiopathology, Acute coronary syndrome complications/mortality/
physiopathology, Hospital Mortality, Saudi Arabia/epidemiology, Prospective Studies
Background
Heart failure (HF) continues to be a significant cause of
morbidity and mortality worldwide [1–3], and a prior
history of coronary artery disease is present in over half
of the acute HF (AHF) patients admitted to the hospital
[4–8]. Data from acute coronary syndrome (ACS) regis-
tries indicate that ACS complicated by HF (ACS-AHF)
leads to a several-fold increase in hospital mortality
compared to those without AHF [9–11]. Additionally,
the adverse effects of ACS-AHF appear to extend be-
yond hospital discharge and up to one year following the
index event [11, 12]. Moreover, a substantial proportion
of hospitalized ACS patients develop AHF during their
hospital course, and carries worse prognosis than those
who present initially with ACS and AHF. Despite the
high-risk status of ACS-AHF patients-, these patients are
undertreated compared to ACS patients without AHF
[13]. Although the clinical characteristics, therapies, and
outcomes of ACS-AHF are well described in the context
of ACS registries, i.e. in patients who present initially and
overtly with ACS, little is known about the outcomes of
these patients compared to the outcomes of AHF patients
without concomitant ACS (NACS-AHF). AHF represents
a syndrome that has a heterogeneous pathophysiology
with variable outcomes. Thus, it is of interest to compare
a group with unique pathophysiology and therapeutic tar-
gets such as ACS-AHF to NACS-AHF patients. Accord-
ingly, we determined the prevalence, clinical correlates,
and hospital therapies of ACS-AHF in a large contempor-
ary HF registry. Additionally, we explored the impact of
ACS presentation on hospital outcomes and on the short-
and long-term mortality of patients hospitalized for AHF.
Methods
The design and rational of the HEARTS registry were
described previously [2, 14]. Briefly, HEARTS is the first
prospective HF registry in Saudi Arabia and the Arab
Middle East. It enrolled 2609 consecutive patients who
were admitted to the hospital with a primary diagnosis
of AHF. Patients younger than 18 years of age who were
unable to provide consent were excluded from the study.
The registry included data from 18 hospitals in differ-
ent regions of Saudi Arabia between October 2009 and
December 2010, with follow-up until January 2013. Six
of the 18 hospitals participating in this study did not have
cardiac catheterization laboratories or cardiac surgery facil-
ities. The diagnosis of AHF was made according to the
European Society of Cardiology guidelines for the diagnosis
and management of acute and chronic HF [15]. For this
analysis, we stratified the enrolled AHF patient population
into two groups: those who had evidence of ACS concomi-
tant with AHF at hospital presentation (ACS-AHF) vs.
those without ACS (NACS-AHF). The ACS group com-
prised patients with ST elevation myocardial infarction
(STEMI) and patients with non-ST acute coronary syn-
drome (NSTACS). The treating physician determined
which patients had ACS based on the presenting symptoms
and clinical context, on electrocardiography (ECG) findings,
as well as on cardiac biomarker levels. The definitions for
STEMI and NSTACS were based on the American College
of Cardiology clinical data standards [16, 17]. Troponin as-
says were performed at initial emergency department as-
sessment and were performed at the physicians’ discretion.
The assay cut-off values were determined by each partici-
pating hospital biochemistry lab according to their values
for what constituted a positive troponin level. Data for
30-day, 1-year, 2-year, and 3-year all-cause mortality were
obtained from each hospital by a telephone inquiry. We
compared the clinical characteristics, hospital manage-
ment, and adverse outcomes, as well as short-term and
long-term all-cause mortality, following the index admis-
sion between the two groups. The study was approved by
the institutional review board at each hospital and com-
plied with the tenets of the Helsinki Declaration. The
study was granted a waiver for consent because the study
carried no more than minimal risk for the patients, the
waiver do not affect adversely the rights and welfare of re-
cruited patients and data management of the study carried
no more than minimal risk to privacy of the patients and
maintained high standards for confidentiality. Further-
more, verbal consent was obtained from recruited patients
“out of courtesy” and to establish rapport with them.
Statistical analysis
Categorical data were summarized as absolute numbers
and percentages. Numeric data were summarized as means
and standard deviations (SD) or as medians and interquar-
tile ranges. Comparisons between different groups were
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performed using the chi-square test or Fisher’s exact for
categorical variables and independent sample t-test or
the Mann-Whitney U test for continuous variables. The
adjusted odds ratios were estimated using multiple logistic
regression. Model adjustment was performed using the
following variables: age, sex, history of HF, ischemic heart
disease (IHD), history of percutaneous coronary inter-
vention (PCI), history of coronary artery bypass surgery
(CABG), diabetes mellitus (DM), hypertension, anemia,
body mass index, estimated glomerular filtration rate
(eGFR) as calculated by the chronic kidney disease epi-
demiology collaboration equation (CKD-EPI) [18], systolic
blood pressure, diastolic blood pressure, heart rate, AHF
type (de novo and acute on chronic HF), and LV systolic
dysfunction. A multiple logistic regression model with
stepwise selection and backward elimination was used to
identify predictors of 3-year mortality, and a 5 % signifi-
cance level was used to remain in the model. Logistic re-
gression with an interaction term was used to test the
statistical significance of interactions between selected
study groups, and we estimated the strength of the associ-
ations of these groups using odds ratios with 95 % confi-
dence intervals. Kaplan-Meier analysis was used to plot
the cumulative survival, and differences between groups
were assessed by the log-rank test. All analyses were
performed using SAS/STAT software, version 9.2 (SAS In-
stitute Inc., Cary, NC, USA) and R (Foundation for Statis-
tical Computing, Vienna, Austria). A 2-sided p-value < 0.05
was considered statistically significant.
Results
Clinical characteristics
Of the 2609 patients with AHF who were included in
this study, 725 (27.8 %) patients had concomitant ACS
(38.1 % STEMI and 61.9 % NSTACS). Compared to
NACS-AHF patients, patients with ACS-AHF were on
average two years older (p = 0.003) and were more likely
to be male (p < 0.001) (Table 1). Risk factors for athero-
sclerosis such as DM, hyperlipidemia, and smoking were
significantly more common in ACS-AHF patients. More-
over, established vascular disease, such as IHD and periph-
eral arterial disease, was more frequent in ACS-AHF
patients. On the other hand, 72.2 % of NACS-AHF patients
had a past history of HF compared to 43.5 % of ACS-AHF
patients (p < 0.001), and NACS-AHF patients more often
had other comorbidities such as a past history of rheumatic
heart disease, atrial fibrillation (AF), anemia, CKD, chronic
liver disease, thyroid disease, and chronic lung disease.
Several differences were noted with respect to clinical
presentation. A significant proportion of ACS-AHF pa-
tients presented with de novo HF (56.6 %), while 71.9 %
of NACS-AHF patients presented with acute on chronic
HF (p < 0.001). NACS-AHF patients were more likely to
present with AF (21.1 % vs. 7.2 %, p < 0.001) and to have
a QRS duration ≥120 ms. Significant differences between
the two groups were noted for several biochemical pa-
rameters (Table 1). Notably, ACS-AHF patients had sig-
nificantly higher mean random blood sugar (RBS), with
the mean value (11.43 ± 6.2 mmol/l) being in the hyper-
glycemia range; on the other hand, NACS-AHF patients
had lower hemoglobin levels (p < 0.001 for both compari-
sons). Approximately 10 % of the NACS-AHF group were
positive for troponin I. Serum NT-ProBNP testing was
only performed in 16.7 % of the total cohort, and its con-
centration in the ACS-AHF group was more than double
that in the NACS-AHF group (p < 0.001). Patients with
NACS-AHF were more likely to have severe left ventricu-
lar (LV) systolic dysfunction (ejection fraction (EF) <30 %)
on echocardiography compared to ACS-AHF patients. In
contrast, ACS-AHF patients were more likely to have mild
and moderate LV systolic dysfunction (Table 1).
Hospital procedures and medical therapy
The use of intra-aortic balloon pumps (IABP) and mechan-
ical ventilation was higher in ACS-AHF patients (Table 2).
Coronary angiography (CAG) was performed in 29.3 % of
the total cohort, and its performance was more than double
in ACS-AHF compared to NACS-AHF patients. Single- or
multi-vessel coronary disease was documented more
frequently in ACS-AHF patients, while normal or non-
significant coronary artery disease was more frequent
in NACS-AHF patients. The use of intravenous nitro-
glycerine and dopamine was greater in ACS-AHF patients.
Upon discharge, patients with ACS-AHF were more likely to
be prescribed aspirin, statins, β-blockers, and angiotensin-
converting enzyme (ACE) inhibitors. Conversely, the
use of diuretics (furosemide and metolazone), aldoster-
one antagonists (AAs), hydralazine, and oral anticoagu-
lants was higher in patients with NACS-AHF (Table 2).
Hospital course
ACS-AHF patients were more likely to suffer from shock
(cardiogenic, non-cardiogenic, or both), although there
was no significant difference in the rate of cardiogenic
shock between the two groups (p = 0.132) (Table 3).
Additionally, the rate of recurrent HF, sepsis, and stroke
or transient ischemic attack (TIA) was higher in ACS-AHF
patients (Table 3). Malignant ventricular arrhythmias re-
quiring therapy and pacing rates for brady-arrhythmias
were encountered more frequently in ACS-AHF patients,
but AF requiring therapy was more frequent in NACS-
AHF patients.
Mortality
Overall hospital, 30-day, 1-year, 2-year and 3-year cumu-
lative mortality data are presented in Table 3. The Crude
hospital and 30-day mortality rates were significantly
higher in ACS-AHF patients (8.8 % vs. 5.6 %, p = 0.003
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n = 725 (27.79 %)
NACS-ACS
n = 1884 (72.21 %)
P value
Demographics
Age, years; mean ± SD 61.34 ± 15 62.74 ± 13.1 60.80 ± 15.6 0.003
Male, n (%) 1717 (65.81) 535 (73.79) 1182 (62.74) <0.001
Saudi nationality, n (%) 2230 (85.47) 546 (75.31) 1684 (89.38) <0.001
Medical history
Heart failure, n (%) 1670 (64.2) 315 (43.5) 1355 (72.2) <0.001
Ischemic heart disease, n (%) 1376 (53.3) 433 (60.1) 943 (50.6) <0.001
PCI, n (%) 340 (13.1) 109 (15.0) 231 (12.3) 0.064
CABG, n (%) 261 (10.0) 52 (7.2) 209 (11.1) 0.003
Rheumatic heart disease, n (%) 183 (7.1) 4 (0.5) 179 (9.6) <0.001
Atrial fibrillation, n (%) 408 (15.7) 37 (5.1) 371 (19.8) <0.001
ICD, n (%) 229 (8.8) 31 (4.3) 198 (10.5) <0.001
CRT, n (%) 85 (3.3) 7 (0.8) 78 (4.1) <0.001
Stroke/TIA, n (%) 252 (9.7) 67 (9.2) 185 (9.8) 0.637
PAD, n (%) 99 (3.8) 37 (5.1) 62 (3.3) 0.034
Anemia, n (%) 1166 (44.9) 301 (41.7) 865 (46.2) 0.043
Chronic lung disease, n (%) 185 (7.1) 37 (5.1) 148 (7.9) 0.013
Chronic kidney disease, n (%) 771 (29.7) 163 (22.5) 608 (32.4) <0.001
Liver disease, n (%) 91 (3.5) 9 (1.2) 82 (4.4) <0.001
Thyroid disorder, n (%) 172 (6.8) 28 (4.0) 144 (7.9) <0.001
Risk factors for atherosclerosis
Smoking, n (%) 467 (17.9) 182 (25.1) 285 (15.1) <0.001
Hypertension, n (%) 1831 (70.6) 506 (70.8) 1325 (70.5) 0.914
Dyslipidemia, n (%) 894 (36.4) 289 (42.7) 605 (34.0) <0.001
Diabetes mellitus, n (%) 1668 (64.1) 518 (72.0) 1150 (61.1) <0.001
Clinical parameters on presentation
Acute de novo HF, n (%) 939 (36.0) 410 (56.5) 529 (28.1) <0.001
Acute on chronic HF, n (%) 1670 (64.0) 315 (43.4) 1355 (71.9)
BMI, kg/m2; mean ± SD* 29.16 ± 6.7 28.12 ± 5.4 29.55 ± 7.1 <0.001
SBP, mean ± SD 128.7 ± 31.3 126.6 ± 29.8 129.5 ± 31.9 0.038
DBP, mean ± SD 74.10 ± 17.9 73.67 ± 17.1 74.26 ± 18.2 0.454
HR, mean ± SD 88.8 ± 21.0 89.7 ± 19.1 88.5 ± 21.7 0.185
Investigations
Electrocardiography
Atrial fibrillation/flutter, n (%) 449 (17.2) 52 (7.2) 397 (21.1) <0.001
QRS ≥120 msec, n (%) 389 (14.9) 68 (9.4) 321 (17.1) <0.001
LBBB, n (%) 305 (11.7) 62 (8.5) 243 (12.9) 0.002
Biochemical parameters
Sodium, mmol/L; mean ± SD 135.1 ± 5.3 135.0 ± 5.4 135.2 ± 5.3 0.322
Potassium, mmol/L; mean ± SD 4.3 ± 0.7 4.2 ± 0.7 4.3 ± 0.7 0.644
Urea, μmol/L; mean ± SD 11.87 ± 9.1 11.11 ± 8.4 12.16 ± 9.3 0.008
Creatinine, μmol/L; median (IQR] 109.0 (70.0) 109.0 (62.0) 109.0 (73.0) 0.923
eGFR, ml/min/1.73 m2; median (IQR) 57.28 (43.5) 56.32 (41.9) 57.82 (44.1) 0.444
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and 10.1 % vs. 7.4 %, p = 0.04, respectively), while there
were no differences in the 1-, 2-, or 3-year cumulative
mortality rates between the two groups.
The unadjusted hospital and 30-day mortality rates
were significantly higher in ACS-AHF patients (OR = 1.6
(95 % CI, 1.2–2.2), p = 0.003 and 1.40 (95 % CI, 1.0–1.9),
p = 0.026, respectively) (Table 4). After adjustment for
important demographic characteristics, past vascular his-
tory, important comorbidity risk factors for atheroscler-
osis, renal function, and LV dysfunction, ACS-AHF was
only predictive of hospital mortality (OR = 1.61 (95 % CI,
1.1–2.4), p = 0.019) (Table 4).
We looked at the interaction between ACS that was
concomitant with AHF and hospital mortality in several
important clinical groups, including AHF type (de novo
and acute on chronic), age groups (≥ or <65 years of
age), and LVEF level (≥ or <40 %). AHF with ACS was a
predictor of hospital mortality across all selected groups;
however, its predictive power was heterogeneous, de-
pending on the LVEF cut-off (for EF < 40 %, OR = 1.9
(95 % CI, 1.3–28) and for EF ≥ 40 %, OR = 0.6 (95 % CI
0.2–1.3), p = 0.02 for the interaction) (Fig. 1).
The 3-year survival of ACS-AHF and NACS-AHF pa-
tients was not significantly different (log-rank test, p =
0.67) (Fig. 2a). There was no survival difference between
AHF patients presenting with STEMI or NSACS (Fig. 2b).
The survival of patients with ACS-AHF and LVEF <40 %
was significantly lower than that of patients with
LVEF >40 % (log-rank test, p = 0.001); conversely, no
survival difference was noted in patients with NACS-
AHF with EF above or below 40 % (Fig. 3a and b). Al-
though an EF < 40 % seemed to have a similar impact on
survival in the two groups, ACS-AHF patients had signifi-
cantly higher survival if the EF was ≥40 % compared to
NACS-AHF patients with the same EF cut-off (log-rank
test, p = 0.005) (Fig. 3c and d).
Because it was clear that the two heart failure groups
(ACS-AHF and NACS-AHF) were different, we sought
to determine whether the two groups have similar or dif-
ferent predictors of long-term mortality. Therefore, we
used logistic regression analysis to identify the 3-year in-
dependent predictors of mortality in the two groups.
The independent predictors of mortality in ACS patients
were age, eGFR, heart rate, and LV systolic function. For
patients with no ACS, the independent predictors of
mortality were age, DM, hypertension, history of stroke/
transient ischemic attacks, RBS, systolic blood pressure,
serum urea, and hemoglobin (Table 5).
Discussion
Our study is one of a few that compare the outcomes of
patients admitted to the hospital with AHF and con-
comitant ACS to patients with AHF and no ACS in the
context of a contemporary HF registry. Approximately a
third of the registry population that was admitted with
AHF had concomitant ACS, which is in accordance with
several previous reports [8, 19–21]. We found that AHF
with ACS is a distinct entity with respect to clinical
presentation, clinical correlates, and hospital outcomes.
ACS-AHF patients were older than NACS-AHF patients
and were at higher risk of cardiovascular events by
virtue of their past vascular history and risk factors, not-
ably the astonishingly high DM rates. However, they had
far fewer comorbidities and were more likely to be HF
naïve. This is in stark contrast to the NACS-AHF group,
in which more than 70 % had chronic HF.
The main finding of our study was that ACS-AHF pa-
tients had higher hospital mortality as well as higher
hospital adverse cardiovascular outcomes. Notably, the
intermediate and long-term mortality was not different
compared to NACS-AHF patients. To our knowledge,
only two published reports have addressed the outcomes
Table 1 Baseline characteristics of acute heart failure patients with and without acute coronary syndrome (Continued)
Hemoglobin, g/dL; mean ± SD 12.43 ± 2.2 12.76 ± 2.3 12.31 ± 2.2 <0.001
RBS, mmol/L; mean ± SD 10.01 ± 5.7 11.43 ± 6.2 9.45 ± 5.4 <0.001
NT-Pro-BNP, pmol/L; n (%) 435 (16.7) 101 (13.9) 334 (17.7) 0.019
NT-Pro-BNP, pmol/L; median (IQR) 675.0 (668) 999.0 (1679) 631.5 (684) <0.001
Positive troponin, n (%) 867 (37.4) 693 (98.6) 174 (10.8) <0.001
Echocardiography
Left ventricular EF >55 %, n (%) 341 (13.7) 50 (7.2) 291 (16.2) <0.001
Left ventricular EF 40–54.9 % 334 (13.4) 113 (16.2) 221 (12.3) <0.001
Left ventricular EF 30–9.9 % 632 (25.3) 258 (37.1) 374 (20.8) <0.001
Left ventricular EF <30 % 1187 (47.6) 275 (39.5) 912 (50.7) <0.001
Abbreviations: ACS-AHF acute coronary syndrome with acute heart failure, ACS-NASC no acute coronary syndrome with acute heart failure, BMI body mass index,
BNP brain natriuretic peptide, CABG coronary artery bypass surgery, CRT cardiac resynchronization therapy, DBP diastolic blood pressure, EF ejection fraction, eGFR
estimated glomerular filtration rate, HR heart rate, ICD internal cardiac defibrillator, LBBB left bundle branch block, PAD peripheral artery disease, PCI percutaneous
coronary intervention, RBS random blood sugar, SD standard deviation, SBP systolic blood pressure, TIA transient ischemic attack
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of a comparable cohort. Our findings are in accordance
with the findings of the Finnish Acute Heart Failure
Study (FINN-AKVA) with respect to a higher risk of
mortality in the short-term and an equivalent risk on the
long-term but stand apart from another report that
found that the long –term survival is lower in ACS-AHF
patients [22, 23]. A few reports have highlighted the un-
favorable long-term outcome of acute on chronic HF
compared to de novo HF, including a report from our
group [24–27]. Yet patients with ACS-AHF in our study,
the majority of whom had de novo AHF, were not only
at higher risk for hospital adverse cardiovascular out-
comes but also had similar long-term survival rates com-
pared to patients with NACS-AHF who predominantly
presented with acute on chronic HF. The equivalent
long-term survival between the two groups is a somber
reality and underscores the excessive risk of mortality
beyond hospital discharge and up to three years, presum-
ably because of the older age of the ACS-AHF group, and
the extensive coronary artery disease documented in their
diagnostic CAG.
ACS concomitant with AHF is an independent pre-
dictor of mortality, and its detrimental effect appeared
to be consistent across several selected patient subgroups.
However, this effect was heterogeneous, depending on the
LVEF cut-off that was used (Fig. 1). We found that a low
EF adversely impacted survival to a similar degree in AHF
patients with and without ACS. Although many studies
have demonstrated that HF with reduced EF (HFREF)
have higher mortality compared to HF with preserved
systolic function (HFPEF) [28], in our cohort this was true
only in AHF patients with ACS, presumably because




n = 725 (27.79 %)
NACS-ACS
n = 1884 (72.21)
P value
Hospital procedures and therapies
IV nitroglycerine, n (%) 725 (27.8) 397 (54.8) 328 (17.4) <0.001
Dopamine, n (%) 468 (17.9) 156 (21.5) 312 (16.6) 0.003
Invasive ventilation (%) 289 (11.1) 106 (14.6) 183 (9.7) <0.001
IABP, n (%) 86 (3.3) 57 (7.9) 29 (1.5) <0.001
Cardiac pacing, n (%) 36 (1.38) 18 (2.48) 18 (0.96) 0.003
Hospital ICD, n (%) 150 (5.75) 32 (4.41) 118 (6.26) 0.069
Hospital CRT, n (%) 68 (2.61) 9 (1.24) 59 (3.13) 0.007
CAG performed, n (%) 764 (29.3) 338 (46.6) 426 (22.6) <0.001
Normal coronaries, n (%) 183 (24.0) 9 (2.7) 174 (40.9) <0.001
Non-significant CAD 82 (10.7) 14 (4.1) 68 (16.0) <0.001
Single-vessel CAD, n (%) 105 (13.7) 56 (16.6) 49 (11.5) 0.043
Double-vessel CAD, n (%) 116 (15.2) 77 (22.8) 39 (9.2) <0.001
LM or three-vessel CAD, n (%) 263 (34.4) 179 (53.0) 84 (19.7) <0.001
Discharge medications
Aspirin, n (%) 1989 (76.2) 633 (87.3) 1356 (72.0) <0.001
Warfarin, n (%) 484 (18.5) 56 (7.7) 428 (22.7) <0.001
Statin, n (%) 1813 (69.5) 605 (83.4) 1208 (64.1) <0.001
Lasix, n (%) 2048 (78.5) 546 (75.3) 1502 (79.7) 0.014
Metolazone, n (%) 115 (4.4) 17 (2.3) 98 (5.2) 0.001
Hydralazine, n (%) 300 (11.5) 61 (8.4) 239 (12.7) 0.002
Long-acting nitrates, n (%) 252 (9.7) 103 (14.2) 149 (7.9) <0.001
Amiodarone, n (%) 75 (2.9) 14 (1.9) 61 (3.2) 0.074
Βeta-blockers, n (%) 2180 (83.0) 635 (87.6) 1545 (82.0) <0.001
ACEI, n (%) 1554 (59.6) 463 (63.9) 1091 (57.9) 0.006
ARBI, n (%) 388 (14.9) 95 (13.1) 293 (15.5) 0.115
AA, n (%) 999 (38.4) 191 (26.3) 808 (42.9) <0.001
Abbreviations: AA aldosterone antagonist, ACEI angiotensin-converting enzyme inhibitor, ACS-AHF acute coronary syndrome with acute heart failure, ACS-NASC no
acute coronary syndrome with acute heart failure, ARBI angiotensin receptor blocker, CAG coronary angiography, CRT cardiac resynchronization therapy,
IABP intra-aortic balloon pump, ICD internal cardiac defibrillator, IV intravenous, LM left main
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HFPEF patients without ACS in our patient cohort were
at very high risk of mortality. Another intriguing finding is
that HFPEF patients with no ACS showed significantly
lower survival compared to their counterparts with ACS.
The reason for the lower survival of HFPEF patients
without ACS is unclear, but it is plausible that the lower
survival can be explained by the higher prevalence of both
cardiac and non-cardiac comorbidities compared to pa-
tients with ACS (data not shown). The prognosis of HFPEF
patients is strongly linked to underlying non-cardiac co-
morbidities, such as chronic lung or liver disease [29, 30].
Additionally, anti-HF therapies can often be countered or
blunted by pharmacological agents used for treating these
non-cardiac comorbidities [29, 30].
Our data highlight several important differences in
hospital therapies in the two groups. The high use of
IABPs and inotropes in ACS-AHF patients likely reflects
the high rates of shock, though it is important to note that
the rate of cardiogenic shock was not different between
the two groups, contrary to a previous report [22]. The
use of nitroglycerine, aspirin, statins, and β-blockers in pa-
tients with ACS-AHF is understandably high because
Table 4 Crude and adjusted hospital, short-term, and long-term outcomes in acute heart failure with concomitant ACS
Covariate Crude OR (95 % CI) P value Adjusted OR (95 % CI) P value
Recurrent heart failure 1.24 (1.03–1.48) 0.022 1.66 (1.33–2.06) <0.001
Overall shock 1.95 (1.47–2.57) <0.001 1.85 (1.31–2.60) <0.001
Stroke/TIA 2.44 (1.37–4.32) 0.002 1.87 (0.98–3.56) 0.055
All-cause mortality
Hospital 1.62 (1.17–2.24) 0.003 1.61 (1.08–2.39) 0.019
1-month 1.40 (1.04–1.89) 0.026 1.36 (0.9–1.95) 0.093
1-year 1.07 (0.86–1.32) 0.548 1.16 (0.89–1.51) 0.252
2-year 1.00 (0.81–1.22) 1.000 1.10 (0.85–1.40) 0.462
3-year 0.98 (0.80–1.20) 0.871 1.07 (0.83–1.35) 0.600
Abbreviations: TIA transient ischemic attacks




n = 725 (27.79 %)
NACS-ACS
n = 1884 (72.21)
P value
Hospital course and outcomes
Recurrent CHF, n (%) 816 (31.3) 251 (34.6) 565 (30.0) 0.022
Overall shock, n (%) 228 (8.7) 94 (13.0) 134 (7.1) <0.001
Cardiogenic, n (%) 169 (74.1) 73 (77.7) 96 (71.6) 0.132
Non-cardiogenic, n (%) 22 (9.6) 11 (11.7) 11 (8.2)
Mixed, n (%) 37 (16.2) 10 (10.6) 27 (20.1)
VT/VF requiring therapy, n (%) 110 (4.2) 45 (6.2) 65 (3.4) 0.002
AF requiring therapy, n (%) 156 (6.0) 25 (3.4) 131 (6.9) <0.001
Sepsis, n (%) 196 (7.5) 68 (9.4) 128 (6.8) 0.025
Major bleeding, n (%) 38 (1.5) 14 (1.9) 24 (1.4) 0.209
Stroke/TIA, n (%) 48 (1.8) 23 (3.2) 25 (1.3) 0.002
Hospital stay, days; mean ± SD 12.3 ± 14.6 13.1 ± 15.38 12.0 ± 14.3 0.083
Hospital stay, days; median (IQR) 8.0 (9.0) 8.0 (10.0) 8.0 (9.0) 0.111
All-cause mortality
Hospital, n (%) 170 (6.5) 64 (8.8) 106 (5.6) 0.003
1 month, n (%) 212 (8.1) 73 (10.1) 139 (7.4) 0.044
1 year, n (%) 509 (19.5) 147 (20.3) 362 (19.2) 0.568
2 years, n (%) 615 (23.6) 171 (23.6) 444 (23.6) 0.680
3 years, n (%) 635 (24.3) 175 (24.1) 460 (24.4) 0.671
Abbreviations: ACS-AHF acute coronary syndrome with acute heart failure, ACS-NASC no acute coronary syndrome with acute heart failure, VT ventricular
tachycardia, VF ventricular fibrillation, AF atrial fibrillation, TIA transient ischemic attacks
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these are standard therapies for ACS and IHD in general.
The lower use of ACE inhibitors in the NACS-AHF pa-
tients might be related to the significantly higher propor-
tion of preserved EF in this group. Additionally, the use of
diuretics and AAs was higher in the NACS-AHF patients.
Congestive symptoms tend to be higher in patients with
chronic HF, and as previously noted, acute on chronic HF
was more frequent in the NACS-AHF group [22, 23, 25].
In addition, almost half the NACS-AHF cohort had severe
LV systolic dysfunction, and that, along with chronic HF,
could explain the higher use of AAs in NACS-AHF pa-
tients as well as the higher implantation rates of internal
cardiac defibrillators/cardiac resynchronization therapy.
Given the fact that the NACS-AHF group more often had
a past history of AF, as well more often had incident AF, it
is not surprising that the prescription of oral anticoagula-
tion therapy was also high. Overall, the rate of perform-
ance of CAG was low in this cohort, and it was performed
in less than half of the ACS-AHF cohort. Nonetheless,
CAG was performed more than twice as often in patients
with ACS-AHF than with NACS-AHF, and the finding of
higher significant coronary disease in this group is to be
expected. Although we did not collect data on revasculari-
zation rates, it is conceivable that these rates are even
Fig. 2 Kaplan-Meier survival curves between: a acute heart failure with (solid line) and without acute coronary syndrome (dashed line), b ST elevation
myocardial infarction (solid line) and Non ST acute coronary syndrome (dashed line)
Fig. 1 Interaction between acute coronary syndrome with acute heart failure and hospital mortality in selected patients groups
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Table 5 Predictors of 3-year all-cause mortality, after adjustment for multiple variates, in acute heart failure with or without acute
coronary syndrome





Acute heart failure with ACS
Age (for every 1 year increase) 1.02 1.00 1.04 0.015
eGFR (for every 5 mL/min/1.73 m2 decrease) 1.09 1.03 1.16 <0.001
HR (for every 5 beats/min increase) 1.09 1.03 1.15 0.004
Mild LV dysfunction EF 40 %–49.9 % 1.02 0.36 2.87 0.976
Moderate LV dysfunction EF 30–39.9 % 2.37 0.96 5.82 0.060
Severe LV dysfunction EF <30 % 2.78 1.14 6.78 0.024
Acute heart failure without ACS
Age (for every 1 year increase) 1.03 1.02 1.04 <0.001
Diabetes mellitus 0.61 0.46 0.83 0.001
Hypertension 1.45 1.04 2.01 0.027
Stroke/TIA 1.54 1.06 2.25 0.025
RBS (for every 1 mmol/L increase) 1.03 1.01 1.06 0.006
SBP (for 1 mmHg increase) 0.99 0.99 1.00 <0.001
Urea (for every 1 μmol/L increase) 1.05 1.03 1.06 <0.001
Hemoglobin (for every 1 g/dL increase) 0.88 0.83 0.93 <0.001
Abbreviations: ACS acute coronary syndrome, EF ejection fraction, eGFR estimated glomerular filtration rate, LV left ventricular, RBS random blood sugar, SBP
systolic blood pressure, TIA transient ischemic attacks
Fig. 3 Kaplan-Meier survival curves between: a Acute coronary syndrome (ACS) with ejection (EF) <40 % (solid line) and ACS with EF≥ 40 %, b No
ACS <40 % (solid line) and No ACS with EF≥ 40 %, c ACS with EF <40 % (solid line) and no ACS with EF <40 % (dashed line), d ACS with≥ 40 %
(solid line) and No ACS with EF≥ 40 % (dashed line)
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lower in the context of the low rates of diagnostic CAG.
Moreover, 60 % of patients presenting with ACS in our co-
hort had a past history of IHD; therefore, it could be ar-
gued that prior knowledge of their coronary anatomy
might have influenced the decision to perform CAG and
subsequent revascularization if indicated. Furthermore,
some physicians might have scheduled the CAG after hos-
pital discharge when the HF symptoms would be fully
resolved.
The reasons underlying the dire outlook of ACS-AHF
patients are unclear. Favorable clinical outcomes in ACS
depend on rapid diagnosis and risk assessment that leads
to timely therapy [17, 31]. The presentation of AHF
might on certain occasions obscure concomitant ACS,
which in turn could delay risk stratification and rapid
treatment [32]. Unfortunately, patients with a combination
of ACS and AHF tend to be undertreated and thus to
undergo less invasive therapies [11]. Moreover, ischemia
often leads to increased myocardial stress and cardio-
myocyte damage, and NT-proBNP and troponin are two
biomarkers linked to myocardial stress and damage [32].
Indeed, we found that both markers were significantly
higher in the ACS-AHF group than in the NACS-AHF
group.
Our findings highlight the fact that the intersection of
ACS and AHF results in a unique HF entity both in terms
of pathophysiology and therapeutic targets. Accordingly,
future clinical trials that investigate new therapeutic
agents for HF should take into account the uniqueness
of this entity rather than including these groups of pa-
tients in the general pool of AHF patients.
This study has several limitations. Participation in this
registry was voluntary, so selection bias cannot be ex-
cluded. Nonetheless, enrolling consecutive patients should
minimize this limitation. Although the diagnosis of ACS
was guided by the protocol, the diagnosis was based
largely on the physician’s judgment of the clinical context
and presenting symptoms along with the ECG and cardiac
biomarker findings. This could lead to under or over
diagnosis of ACS. However, the rates of ACS in our co-
hort were comparable to those in previous HF registries
[8, 19–21]. We did not collect data on hospital coron-
ary revascularization, but the rate is likely to be low in
view of the low performance of CAG. We also did not
collect post-discharge data pertaining to re-hospitalization,
compliance with medical therapy, or revascularization
procedures, and these data could influence the long-term
outcomes.
Conclusion
ACS-AHF patients differ from NACS-AHF patients in
their baseline characteristics, baseline risk level, and car-
diovascular outcomes. Future research should focus on
developing timely diagnostic and therapeutic strategies
to improve the outcomes of this high-risk group.
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